129 research outputs found
ER5, a tomato cDNA encoding an ethylene-responsive LEA-like protein: characterization and expression in response to drought, ABA and wounding
No full textWe report the isolation by differential display of a novel tomato ethylene-responsive cDNA, designated ER5. RT-PCR analysis of ER5 expression revealed an early (15 min) and transient induction by ethylene in tomato fruit, leaves and roots. ER5 mRNA accumulated during 2 h of ethylene treatment and thereafter underwent a dramatic decline leading to undetectable expression after 5 h of treatment. The full-length cDNA clone of 748 bp was obtained and DNA sequence analysis showed strong homologies to members of the atypical hydrophobic group of the LEA protein family. The predicted amino acid sequence shows 67%, 64%, 64%, and 61%sequence identity with the tomato Lemmi9, soybean D95-4, cotton Lea14-A, and resurrection plant pcC27-45 gene products, respectively. As with the other members of this group, ER5 encodes a predominantly hydrophobic protein. Prolonged drought stress stimulates ER5 expression in leaves and roots, while ABA induction of this ethylene-responsive clone is confined to the leaves. The use of 1-MCP, an inhibitor of ethylene action, indicates that the drought induction of ER5 is ethylene-mediated in tomato roots. Finally, wounding stimulates ER5 mRNA accumulation in leaves and roots. Among the Lea gene family this novel clone is the first to display an ethylene-regulated expression
Design and validation of an instrument for the identification of look-alike drug in the primary packaging of injectables products
No full textilustraciones, fotografías, gráficas, tablasLa isoapariencia es la semejanza en el empaque o etiquetado de los medicamentos que aumenta la probabilidad de cometer errores durante la atención en salud. A nivel mundial, cada país es libre de gestionar estos riesgos mediante la implementación de barreras de seguridad para que no se desencadenen errores de medicación en un paciente. El objetivo de esta investigación consistió en diseñar y validar un instrumento mediante la caracterización de los atributos mínimos en el empaque primario de los medicamentos inyectables que permita identificar su isoapariencia. Los materiales y métodos para el desarrollo de esta tesis de maestría consistieron en seis etapas. En la primera se realizó una revisión bibliográfica exhaustiva y exploración del portal Datos Abiertos. Para la segunda se conformó un grupo Delphi con expertos a nivel nacional e internacional. En la tercera se diseñó un instrumento para la recolección y análisis de la información. La cuarta consistió en pilotar el instrumento en una institución de baja complejidad. En la quinta se validó estadísticamente el instrumento. La sexta se orientó a construir una herramienta digital. Como resultados se identificaron 36 atributos que permiten evaluar la isoapariencia en el empaque primario de los medicamentos inyectables, los cuales fueron validados por 17 expertos. Además, se construyó la primera plataforma web 2.0 no-code pública denominada ISOFARINY©. En conclusión, la isoapariencia en Colombia sí existe y el instrumento desarrollado en esta investigación permitirá identificar de manera objetiva las parejas de medicamentos inyectables que son fallas activas en el conjunto de productos farmacéuticos comercializados a nivel local, nacional o mundial para diseñar estrategias que minimicen el riesgo por parte de los diferentes actores involucrados en la cadena logística del medicamento. (Texto tomado de la fuente).The look-alike drug is the similarity in the packaging or labeling of medicines that increases the probability of making errors during health care. Worldwide, each country is free to manage these risks by implementing security barriers so that medication errors are not triggered in a patient. The objective of this research was to design and validate an instrument by characterizing the minimum attributes in the primary packaging of injectable products that allows identifying their look-alike drug. The materials and methods for the development of this master's thesis consisted of six stages. In the first, an exhaustive bibliographic review and exploration of the portal “Datos Abiertos” was carried out. For the second, a Delphi group was formed with national and international experts. In the third, an instrument was designed for the collection and analysis of information. The fourth consisted of piloting the instrument in a low-complexity institution. In the fifth, the instrument was statistically validated. The sixth was aimed at building a digital tool. As results, 36 attributes were identified that allow evaluating the look-alike drug in the primary packaging of injectable products, which were validated by 17 experts. In addition, the first public web 2.0 no-code platform called ISOFARINY© was built. In conclusion, the look-alike drug in Colombia does exist and the instrument developed in this research will make it possible to objectively identify the pairs of injectable drugs that are active failures in the set of pharmaceutical products marketed locally, nationally or globally to design strategies that minimize the risk by the different actors involved in the drug logistics chain.“En tiempos de cambio, quienes estén abiertos al aprendizaje se adueñarán del futuro, mientras que aquellos que creen saberlo todo estarán bien equipados para un mundo que ya no existe” - Eric HofferMaestríaMagíster en Ciencias - FarmacologíaPara el desarrollo de esta tesis de maestría consistieron en seis etapas. En la primera se realizó una revisión bibliográfica exhaustiva y exploración del portal Datos Abiertos. Para la segunda se conformó un grupo Delphi con expertos a nivel nacional e internacional. En la tercera se diseñó un instrumento para la recolección y análisis de la información. La cuarta consistió en pilotar el instrumento en una institución de baja complejidad. En la quinta se validó estadísticamente el instrumento. La sexta se orientó a construir una herramienta digital.FarmacovigilanciaISOFARINY©️ es la primera plataforma web 2.0 colombiana que aborda la situación de alto riesgo de isoapariencia farmacéutica en medicamentos inyectables bajo un entorno digital amigable y atractivo visualmente para sus usuarios finales --> https://www.isofariny.org
Photomodulation multiple sessions as a promising preventive therapy for medication-related osteonecrosis of the jaws after tooth extraction in rats
No full textFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Processo FAPESP: #2012/03067-6Processo FAPESP: #2013/26779-4Processo FAPESP: #2014/02199-1Processo FAPESP: #2014/14118-6CNPq: #28040-2013CNPq: #30699-2014The aim of this study was to evaluate the effects of photobiomodulation (PBM) with multiple sessions of low-level laser on the alveolar repair process of rats with major risk factors for medication-related osteonecrosis of the jaws (MRONJ). Senile rats received 0.45 mL of vehicle (VEH and VEH-PBM) or 0.45 mL of 100 μg/kg zoledronate (ZOL and ZOL-PBM) administrated intraperitoneally every two days during seven weeks. After three weeks of initiation of drug treatment the first lower left molar was extracted. No local treatment was performed in VEH and ZOL. VEH-PBM and ZOL-PBM were submitted to laser irradiation (660 ± 10 nm; 0.035 W; 2.1 J; 60 s) on the extraction site at 0, 2 and 4 days postoperatively. Euthanasia was performed 28 days after tooth extraction. Histological sections of the hemimandible were submitted to histopathological and histomorphometric analysis, as well as to histochemistry for collagen fiber maturation and immunohistochemistry for pro-inflammatory cytokines. In ZOL, general impairment of tissue repair, areas with osteonecrosis, lower newly formed bone tissue (NFBT), smaller amount of mature collagen fibers and increased immunoreactivity for TNFα IL-1β and IL-6 were observed when compared to VEH and VEH-PBM. ZOL-PBM showed significant improvement in some parameters compared to ZOL, such as positive repair tissue, higher NFBT, greater amount of mature collagen fibers, besides TNFα and IL-1β immunoreactivity decrease. Zoledronate treatment severely compromised the tissue repair process of the tooth extraction site in rats with major risk factors for MRONJ. Based on parameters employed in the present study, PBM in multiple sessions can improve the alveolar repair process, constituting a promising preventive therapy to avoid the onset of post-extraction MRONJ
Antimicrobial photodynamic therapy improves the alveolar repair process and prevents the occurrence of osteonecrosis of the jaws after tooth extraction in senile rats treated with zoledronate
No full textFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Processo FAPESP: 2012/03067-6Processo FAPESP: 2013/25367-4Processo FAPESP: 2013/26779-4Processo FAPESP: 2014/02199-1Processo FAPESP: 2015/22395-2CNPq: 28040-2013CNPq: 30699-2014This study evaluated the effects of antimicrobial photodynamic therapy (aPDT) in the alveolar repair of rats with major risk factors for bisphosphonate-related osteonecrosis of the jaws (BRONJ). Senile rats received 0.45 ml of vehicle (VEH and VEH/aPDT) or 0.45 ml of zoledronate (ZOL and ZOL/aPDT) every three days for seven weeks. After three weeks of treatment, the first lower left molar was extracted. VEH/aPDT and ZOL/aPDT were submitted to aPDT on the extraction site at 0, 2 and 4 days postoperatively. Euthanasia was performed 28 days postoperatively and the extraction site was evaluated by clinical, histological, histometric, histochemical and immunohistochemical analysis. ZOL showed tissue repair impairment; lower percentage of newly formed bone tissue (NFBT); higher percentage of non-vital bone tissue (NVBT); fewer mature collagen fibers and increased immunolabeling for tumor necrosis factor (TNFα), interleukin (IL)-1β and IL-6. ZOL/aPDT showed clinical and histological characteristics of the extraction site, percentage of NFBT and percentage of mature collagen fiber similar to VEH. Percentage of NVBT and immunolabeling for inflammatory cytokines in ZOL/aPDT was lower than in ZOL. Immunolabeling for tartarato-resistant acid phosphatase (TRAP) was lower in ZOL and ZOL/aPDT. aPDT in the dental extraction site improves tissue repair process and prevents the occurrence of BRONJ-like lesions after tooth extraction
Application of Autologous Platelet-Rich Plasma on Tooth Extraction Site Prevents Occurence of Medication-Related Osteonecrosis of the Jaws in Rats
No full textFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Processo FAPESP: 2013/26779-4This study evaluated the effects of local application of autologous platelet-rich plasma (PRP) on the tooth extraction site of rats presenting the main risk factors for medication-related osteonecrosis of the jaw (MRONJ). For seven weeks, senile rats were submitted to systemic treatment with vehicle (VEH and VEH-PRP) or 100 μg/Kg of zoledronate (ZOL and ZOL-PRP) every three days. After three weeks, the first lower molar was extracted. VEH-PRP and ZOL-PRP received PRP at the tooth extraction site. Euthanasia was performed at 28 days postoperatively. Clinical, histopathological, histometric and immunohistochemical analyses were carried out in histological sections from the tooth extraction site. ZOL showed lower percentage of newly formed bone tissue (NFBT), higher percentage of non-vital bone tissue (NVBT), as well as higher immunolabeling for TNFα and IL-1β. In addition, ZOL presented lower immunolabeling for PCNA, VEGF, BMP2/4, OCN and TRAP. VEH and ZOL-PRP showed improvement in the tooth extraction site wound healing and comparable percentage of NFBT, VEGF, BMP2/4 and OCN. Local application of autologous PRP proved a viable preventive therapy, which is safe and effective to restore tissue repair capacity of the tooth extraction site and prevent the occurrence of MRONJ following tooth extraction
Consumption of psychoactive substances in young people aged 18 to 20 years old in an I.P.S in the city of Santa Marta in the department of Magdalena
No full textEste proyecto tiene como objetivo entender la percepción que tienen los jóvenes de 18 a 20 años internas en una I.P.S de la ciudad de Santa Marta sobre el consumo de sustancias psicoactivas. Es una investigación cualitativa con diseño fenomenológico, cuyos datos se obtuvieron de un grupo de 3 jóvenes internas en una institución, por medio una entrevista que permitió organizar la información y obtener tres categorías: aspectos personales, asociados a la autopercepción; las condiciones del consumo, entendidas como la percepción acerca de la sustancia de inicio, motivos, antecedentes familiares, y el proceso de rehabilitación que comprende la percepción sobre las expectativas y conocimientos sobre el tratamiento recibido. De esta manera, los hallazgos muestran relación con la literatura científica entre tanto el consumo de sustancias es un fenómeno multicausal asociadas a hogares de familias débiles, presión social, antecedentes familiares.Tabla de Contenidos
Resumen... 1
Capítulo 1. Introducción... 2
Planteamiento del problema... 3
Pregunta de investigación... 4
Objetivo general... 4
Objetivos específicos... 4
Justificación... 4
Capítulo 2. Marco de referencia... 6
Sustancias psicoactivas... 6
Tipos de SPA... 6
Marco conceptual... 11
Marco teórico... 13
Marco Empírico... 14
Capítulo 3. Metodología... 19
Tipo y diseño de investigación... 19
Participantes... 19
Técnicas de recolección de datos... 19
Estrategia del análisis de datos... 19
Consideraciones éticas... 20
Capítulo 4. Resultados... 21
Discusión... 25
Conclusiones... 26
Limitaciones.. 27
Recomendaciones... 27
Referencias bibliográficas (organizar orden alfabético)... 28
Anexos... 32This project aims to understand the perception that young people between 18 and 20 years old inmates in an I.P.S in the city of Santa Marta have about the consumption of psychoactive substances. It is a qualitative research with a phenomenological design, whose data were obtained from a group of 3 young women internally in an institution, through an interview that allowed the information to be organized and three categories obtained: personal aspects, associated with self-perception; the conditions of consumption, understood as the perception about the substance of initiation, motives, family history, and the rehabilitation process that includes the perception about the expectations and knowledge about the treatment received. In this way, the findings show a relationship with the scientific literature, since substance consumption is a multicausal phenomenon associated with homes with weak families, social pressure, and family history
Heritability analysis for several potentially interacting traits in Mediterranean mussel (Mytilus galloprovincialis)
No full textNo abstracts are to be cited without prior reference to the author. Mussel cultivation in Galicia (NW Spain) is the most important activity of the Spanish aquaculture and one of the most relevant of the European marine culture. This is due to both the volume of the production (over 200.000 tons/year) and to the economic and social impact on the productive structure of this region. However, toxic episodes of phytoplankton origin are a serious threat for its production in Galicia. Reduction of toxin impact could be achieved by obtaining strains of mussels with lower toxin accumulation through selective breeding programmes, provided a significant heritability for this trait. The best way to estimate heritabilities is to manage a large set of families reared under a common environment and using a randomized design, and for this, molecular markers represent the best option to identify families at phenotyped individuals. Here we report the genetic component for the accumulation of a specific toxin in Mediterranean mussel after exposure to a toxic phytoplankton bloom in the Galician Rías, and subsequent depuration at indoor facilities using a large set of full (FS) and half-sib (HS) families identified by a microsatellite tool (Pino-Querido et al., 2014). We also took advantage of the founded families to estimate the heritability for other Mediterranean mussel productive traits including growth and body color
Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data
No full text© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.[EN] Background: The objective of the study is to estimate the frequency of multimorbidity in type 2 diabetes patients
classified by health statuses in a European region and to determine the impact on pharmaceutical expenditure.
Methods: Cross-sectional study of the inhabitants of a southeastern European region with a population of
5,150,054, using data extracted from Electronic Health Records for 2012. 491,854 diabetic individuals were identified
and selected through clinical codes, Clinical Risk Groups and diabetes treatment and/or blood glucose reagent
strips. Patients with type 1 diabetes and gestational diabetes were excluded. All measurements were obtained at
individual level. The prevalence of common chronic diseases and co-occurrence of diseases was established using
factorial analysis.
Results: The estimated prevalence of diabetes was 9.6 %, with nearly 70 % of diabetic patients suffering from more
than two comorbidities. The most frequent of these was hypertension, which for the groups of patients in Clinical
Risk Groups (CRG) 6 and 7 was 84.3 % and 97.1 % respectively. Regarding age, elderly patients have more
probability of suffering complications than younger people. Moreover, women suffer complications more frequently
than men, except for retinopathy, which is more common in males. The highest use of insulins, oral antidiabetics
(OAD) and combinations was found in diabetic patients who also suffered cardiovascular disease and neoplasms.
The average cost for insulin was 153€ and that of OADs 306€. Regarding total pharmaceutical cost, the greatest
consumers were patients with comorbidities of respiratory illness and neoplasms, with respective average costs of
2,034.2€ and 1,886.9€.
Conclusions: Diabetes is characterized by the co-occurrence of other diseases, which has implications for disease
management and leads to a considerable increase in consumption of medicines for this pathology and, as such,
pharmaceutical expenditure.This study was financed by a grant from the Fondo de Investigaciones de la Seguridad Social Instituto de Salud Carlos III, the Spanish Ministry of Health (FIS PI12/0037).Sancho Mestre, C.; Vivas Consuelo, DJJ.; Alvis, L.; Romero, M.; Usó Talamantes, R.; Caballer Tarazona, V. (2016). Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data. BMC Health Services Research. 16(394):1-8. https://doi.org/10.1186/s12913-016-1649-2S1816394Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22079683Soriguer F, Goday A, Bosch-Comas A, Bordiu E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the [email protected] Study. Diabetologia. 2012;55:88–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21987347WHO | Rio Political Declaration on Social Determinants of Health. WHO. World Health Organization; 2011. Available from: http://www.who.int/sdhconference/declaration/Rio_political_declaration.pdf?ua=1Fortin M, Soubhi H, Hudon C, Bayliss EA, van den Akker M. Multimorbidity’s many challenges. BMJ. 2007;334:1016–7. BMJ Group [cited 2016 Aug 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17510108Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7:357–63. [cited 2016 Aug 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19597174Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15617955Glynn LG, Valderas JM, Healy P, Burke E, Newell J, Gillespie P, et al. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. Fam Pract. 2011;28:516–23. [Internet]. 2011 [cited 2016 Aug 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21436204Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37–43. [cited 2014 Nov 5] Available from: http://www.ncbi.nlm.nih.gov/pubmed/22579043Holden L, Scuffham PA, Hilton MF, Muspratt A, Ng SK, Whiteford HA. Patterns of multimorbidity in working Australians. Popul Heal Metr. 2011;9:15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21635787Starfield B. Threads and yarns: weaving the tapestry of comorbidity. Ann Fam Med. 2006;4:101–3. [cited 2016 Aug 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16569711Abdul-Rahim HF, Holmboe-Ottesen G, Stene LCM, Husseini A, Giacaman R, Jervell J, et al. Obesity in a rural and an urban Palestinian West Bank population. Int J Obes. 2003;27:140–6. Available from: http://dx.doi.org/10.1038/sj.ijo.0802160Boutayeb A, Boutayeb S, Boutayeb W. Multi-morbidity of non communicable diseases and equity in WHO Eastern Mediterranean countries. Int J Equity Heal. 2013;12:60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23961989Teljeur C, Smith SM, Paul G, Kelly A, O’Dowd T. Multimorbidity in a cohort of patients with type 2 diabetes. Eur J Gen Pract. 2013;19:17–22. Available from: http://informahealthcare.com/doi/abs/10.3109/13814788.2012.714768 , http://www.ncbi.nlm.nih.gov/pubmed/23432037Hughes JS, Averill RF, Eisenhandler J, Goldfield NI, Muldoon J, Neff JM, et al. Clinical Risk Groups (CRGs): a classification system for risk-adjusted capitation-based payment and health care management. Med Care. 2004;42:81–90. [cited 2016 Feb 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14713742Vivas-Consuelo D, Alvis-Estrada L, Uso-Talamantes R, Caballer-Tarazona V, Buigues-Pastor L, Sancho-Mestre C. Multimorbidity Pharmaceutical Cost of Diabetes Mellitus. Value in Health. 2014;17:A341–2. Elsevier [cited 2016 Apr 21]. Available from: http://www.sciencedirect.com/science/article/pii/S1098301514026102Inoriza JM, Pérez M, Cols M, Sánchez I, Carreras M. Análisis de la población diabética de una comarca : perfil de morbilidad, utilización de recursos, complicaciones y control metabólico. Aten Primaria. 2016;45. Available from: http://www.sciencedirect.com/science/article/pii/S0212656713001340Vivas-Consuelo D, Usó-Talamantes R, Trillo-Mata JL, Caballer-Tarazona M, Barrachina-Martínez I, Buigues-Pastor L. Predictability of pharmaceutical spending in primary health services using Clinical Risk Groups. Health Policy. 2014;116:188–95. Available from: http://www.sciencedirect.com/science/article/pii/S0168851014000256Kho AN, Hayes MG, Rasmussen-Torvik L, Pacheco JA, Thompson WK, Armstrong LL, et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc. 2016;19:212–8. [cited 2016 Feb 18]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3277617&tool=pmcentrez&rendertype=abstractPrados-Torres A, Poblador-Plou B, Calderón-Larrañaga A, Gimeno-Feliu LA, González-Rubio F, Poncel-Falcó A, et al. Multimorbidity patterns in primary care: interactions among chronic diseases using factor analysis. PLoS One. 2012;7:e32190. Public Library of Science [cited 2016 Apr 21]. Available from: http://dx.doi.org/10.1371/journal.pone.0032190Islam MM, Valderas JM, Yen L, Dawda P, Jowsey T, McRae IS. Multimorbidity and comorbidity of chronic diseases among the senior Australians: prevalence and patterns. PLoS One. 2014;9:e83783. Public Library of Science [cited 2016 Mar 25]. Available from: http://dx.doi.org/10.1371/journal.pone.0083783Fortin M, Bravo G, Hudon C, Lapointe L, Dubois MF, Almirall J. Psychological distress and multimorbidity in primary care. Ann Fam Med. 2006;4:417–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17003141Nuttall M, van der Meulen J, Emberton M. Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. J Clin Epidemiol. 2006;59:265–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16488357Klompas M, Eggleston E, McVetta J, Lazarus R, Li L, Platt R. Automated detection and classification of type 1 versus type 2 diabetes using electronic health record data. Diabetes Care. 2013;36:914–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23193215Alonso-Moran E, Orueta JF, Fraile Esteban JI, Arteagoitia Axpe JM, Luz Marques Gonzalez M, Toro Polanco N, et al. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country. BMC Public Health. 2014;14. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197247/Pantalone KM, Hobbs TM, Wells BJ, Kong SX, Kattan MW, Bouchard J, et al. Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. BMJ open diabetes Res Care. 2015;3:e000093. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4513350&tool=pmcentrez&rendertype=abstractAlonso-Moran E, Satylganova A, Orueta JF, Nuno-Solinis R. Prevalence of depression in adults with type 2 diabetes in the Basque Country: relationship with glycaemic control and health care costs. BMC Public Health. 2014;14. Available from: http://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-14-769Kilzieh N, Rastam S, Maziak W, Ward KD. Comorbidity of depression with chronic diseases: a population-based study in Aleppo, Syria. Int J Psychiatry Med. 2008;38:169–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18724568Almawi W, Tamim H, Al-Sayed N, Arekat MR, Al-Khateeb GM, Baqer A, et al. Association of comorbid depression, anxiety, and stress disorders with Type 2 diabetes in Bahrain, a country with a very high prevalence of Type 2 diabetes. J Endocrinol Invest. 2008;31:1020–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19169060Giralt Muiña P, Gutiérrez Ávila G, Ballester Herrera MJ, Botella Romero F, Angulo Donado JJ. Prevalencia de diabetes y diabetes oculta en adultos de Castilla-La Mancha. TITLEREVISTA. 2011;137:484–90. Available from: http://zl.elsevier.es/es/revista/medicina-clinica-2/prevalencia-diabetes-diabetes-oculta-adultos-castilla-la-mancha-90028329-originales-2011Mata-Cases M, Roura-Olmeda P, Berengué-Iglesias M, Birulés-Pons M, Mundet-Tuduri X, Franch-Nadal J, et al. Fifteen years of continuous improvement of quality care of type 2 diabetes mellitus in primary care in Catalonia, Spain. Int J Clin Pract. 2012;66:289–98. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3584513&tool=pmcentrez&rendertype=abstractEgede LE, Gebregziabher M, Zhao Y, Dismuke CE, Walker RJ, Hunt KJ, et al. Differential Impact of Mental Health. 2015;21:535–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26295353Huber CA, Diem P, Schwenkglenks M, Rapold R, Reich O. Estimating the prevalence of comorbid conditions and their effect on health care costs in patients with diabetes mellitus in Switzerland. Diabetes Metab Syndr Obes. 2014;7:455–65. Dove Press [cited 2016 Aug 4]. Available from: https://www.dovepress.com/estimating-the-prevalence-of-comorbid-conditions-and-their-effect-on-h-peer-reviewed-article-DMS
The lantern of Zamora cathedral revisited
No full text[EN] The lantern of the cathedral of Zamora is a very unique work in the history of Western architecture. It combines very diverse influences such as the Byzantine, the Islamic and the French Romanesque integrated in a unitary and coherent whole where each part maintains its singularity. As its most outstanding elements, we can mention the construction on pendentives, the circular drum pierced by windows, the ribbed dome, the gored spaces between the ribs, the angle turrets and the central gables. However, it has not been a much portrayed monument with the exception of the drawings made by the restoration architects. This essay aims at analysing minutely the architectural composition of the lantern and showing its elements by means of the drawings and photos of the lantern that the author himself has made together with some panoramic views of the city of Zamora, where the lantern appears as a visual reference.[ES] El cimborrio de la catedral de Zamora es una obra singularísima en la historia de la arquitectura occidental. En ella se combinan influencias muy diversas, como la bizantina, la islámica y la románica francesa, unidas en un todo unitario y coherente, donde cada parte mantiene su singularidad. Destaca su construcción sobre pechinas, su tambor circular calado por ventanas, los nervios que dan forma a la cúpula, los gallones que cierran los espacios entre ellos, las torretas de las esquinas y los gabletes centrales. Sin embargo, no ha sido un monumento muy dibujado, pues apenas existen dibujos de ella fuera de los que han hecho sus propios arquitectos restauradores. En este trabajo se realiza un análisis pormenorizado de su composición arquitectónica y se muestran algunos de los dibujos que el autor le ha dedicado monográficamente a ella; junto a diversas panorámicas de la ciudad de Zamora, donde se puede observar claramente que el cimborrio es una referencia visual de la ciudad.Báez Mezquita, JM. (2018). El cimborrio de la catedral de Zamora revisitado. EGA. Revista de Expresión Gráfica Arquitectónica. 23(34):252-263. https://doi.org/10.4995/ega.2018.10880SWORD2522632334Casaseca Beneitez, Á. 2008. "Piedras de orfebre", en Báez Mezquita, J. M. 2008. Espacios- Acuarelas. Valladolid: Universidad de Valladolid, p. 172.de Champeaux, G. and Sterckx, D. S. 1985. Introducción a los símbolos. Madrid: Encuentro Ediciones (Europa Románica 7).Gómez Moreno, M. 1927. Catálogo Monumental de España - Provincia de Zamora (1903-1905). Madrid: Ministerio de Instrucción y Bellas Artes.Hersey, C. K. 1937. The Salmantine lanterns - Their origins and development. Cambridge, Mass: Harvard University Press.Lambert, E. 1990. El arte gótico en España en los siglos xii y xiii, traducción de Cristina Rodríguez Salmones. Madrid: Cátedra.Lampérez y Romea, V. 1900. El bizantinismo en la arquitectura cristiana española (siglos vi al xii): Sociedad Española de Excursiones. Madrid: Imp. De San Francisco de Sales.Lampérez y Romea, V. 1930. Historia de la arquitectura cristiana española en la Edad Media: según el estudio de los elementos y monumentos. Tomo 1. Madrid: Espasa-Calpe.Menéndez Pidal, L. 1961. "Restauración del cimborrio y de las cubiertas pétreas en la catedral de Zamora". Archivo Español de Arte 34, 135, pp. 193-213. Madrid.Navarro Talegón, J. 1996. "La Catedral de Zamora". Catedrales de Castilla y León: Aquellas blancas catedrales. Tomo 2, pp. 91-97. Valladolid: Consejo autonómico de los Colegios Oficiales de Arquitectos de Castilla y León.Street, G. E. 1926. La arquitectura gótica en España. Edición y ensayo introductorio de López Ulloa F. S. Madrid: Instituto Juan de Herrera, 2015.Torres Balbás, L. 1922. "Los cimborrios de Zamora, Salamanca y Toro". Revista Arquitectura 4, pp. 97-117. Madrid
A Prognostic Score to Identify Low-risk Outpatients with Acute Deep Vein Thrombosis in the Lower Limbs
No full textNo prior studies have identified which patients with deep vein thrombosis in the lower limbs are at a low risk for adverse events within the first week of therapy.sponsorship: The RIETE registry was supported with an unrestricted educational grant from Sanofi Spain and Bayer Pharma AG. (Sanofi Spain, Bayer Pharma AG)status: Publishe
- …
